Literature DB >> 27216218

LNK mutations in familial myeloproliferative neoplasms.

Elisa Rumi1, Ashot S Harutyunyan2, Daniela Pietra3, Jelena D Milosevic Feenstra2, Chiara Cavalloni4, Elisa Roncoroni3, Ilaria Casetti4, Marta Bellini4, Chiara Milanesi3, Maria C Renna3, Manuel Gotti3, Cesare Astori3, Robert Kralovics2, Mario Cazzola1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27216218     DOI： 10.1182/blood-2016-04-711150

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

1.  Buccal epithelial cells display somatic, bone marrow-derived CALR mutation.

Authors:  Scott R Gilles; Linda B Baughn; Matthew L Schomaker; Elizabeth L Courville; Andrew C Nelson; Zohar Sachs
Journal:  Blood Adv       Date:  2017-11-16

Review 2.  The role of LNK/SH2B3 genetic alterations in myeloproliferative neoplasms and other hematological disorders.

Authors:  N Maslah; B Cassinat; E Verger; J-J Kiladjian; L Velazquez
Journal:  Leukemia       Date:  2017-05-09       Impact factor: 11.528

Review 3.  Myeloproliferative neoplasms: from origins to outcomes.

Authors:  Jyoti Nangalia; Anthony R Green
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

Review 5.  Recent insights regarding the molecular basis of myeloproliferative neoplasms.

Authors:  Mi-Ae Jang; Chul Won Choi
Journal:  Korean J Intern Med       Date:  2019-11-29       Impact factor: 2.884

6.  Adaptor protein LNK promotes anaplastic thyroid carcinoma cell growth via 14-3-3 ε/γ binding.

Authors:  Zhao-Ming Zhong; Xue Chen; Xiao Qi; Xue-Min Wang; Chun-Yan Li; Ru-Jia Qin; Shi-Qi Wang; Jin Liang; Mu-Sheng Zeng; Chuan-Zheng Sun
Journal:  Cancer Cell Int       Date:  2020-01-09       Impact factor: 5.722

7.  Concomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia.

Authors:  Lukas Clemens Böckelmann; Titiksha Basu; Albert Gründer; Wei Wang; Jan Breucker; Sandra Kaiser; Andrea Pichler; Heike Luise Pahl
Journal:  Haematologica       Date:  2021-04-01       Impact factor: 9.941

8.  The Missing LNK: Evolution from Cytosis to Chronic Myelomonocytic Leukemia in a Patient with Multiple Sclerosis and Germline SH2B3 Mutation.

Authors:  Krishna Gundabolu; Bhavana J Dave; Carmelita J Alvares; Jeffrey J Cannatella; Vijaya R Bhatt; Lori J Maness; Zaid S Al-Kadhimi; Rana K Zabad; Allison M Cushman-Vokoun
Journal:  Case Rep Genet       Date:  2022-03-01

Review 9.  JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders.

Authors:  William Vainchenker; Emilie Leroy; Laure Gilles; Caroline Marty; Isabelle Plo; Stefan N Constantinescu
Journal:  F1000Res       Date:  2018-01-17

10.  Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms.

Authors:  Jean Pegliasco; Pierre Hirsch; Christophe Marzac; Françoise Isnard; Jean-Côme Meniane; Caroline Deswarte; Philippe Pellet; Céline Lemaitre; Gwendoline Leroy; Graciela Rabadan Moraes; Hélène Guermouche; Barbara Schmaltz-Panneau; Florence Pasquier; Chrystelle Colas; Patrick R Benusiglio; Odile Bera; Jean-Henri Bourhis; Eolia Brissot; Olivier Caron; Samy Chraibi; Pascale Cony-Makhoul; Christine Delaunay-Darivon; Simona Lapusan; Flore Sicre de Fontbrune; Pascal Fuseau; Albert Najman; William Vainchenker; François Delhommeau; Jean-Baptiste Micol; Isabelle Plo; Christine Bellanné-Chantelot
Journal:  Leukemia       Date:  2021-06-25       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.